Biotechnology

A strategic investment firm's move signals strong confidence in the closing of Avadel's multi-billion dollar deal, spotlighting its blockbuster sleep drug.

A new partnership is using AI to make 'living drugs' smarter and more effective, promising to revolutionize manufacturing and bring hope to patients.

A key advisory appointment reveals a pivotal trend in private equity: a move from deal-making to deep operational focus for maximizing portfolio returns.

Trinity Consultants' acquisition of CEQA/NEPA expert Meridian is more than a regional deal; it's a strategic move with deep implications for biopharma.

A new oral drug could eliminate the dangerous side effects of CAR T-Cell therapy, potentially making the breakthrough cancer treatment safer and more accessible.

Stunning trial data reveals an immunotherapy combo that slashes myeloma progression by 83%, offering not just longer life but a better quality of life.

Beyond a simple product launch, a strategic acquisition is fueling innovations in drug delivery that could transform patient care for millions worldwide.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

A.D.A.M. Innovations just launched ALUNAÉ, the world's first AI genomic-based skincare. Is this the future of beauty or a step too far?

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

A fierce bidding war for Avadel Pharmaceuticals reveals the high value of its key drug, as filings from giants like State Street highlight M&A transparency.

Eli Lilly's groundbreaking leukemia drug data signals a major market shift, promising better patient outcomes and fortifying its long-term growth strategy.

AskBio's gene therapies for Parkinson's and heart failure have received Japan's SAKIGAKE designation, promising a faster path to patients.

A new patent for its lead cancer drug in Japan is more than a legal win; it's a strategic move to secure a future market into the 2040s.

Animal health giant Elanco is restructuring its global footprint, betting its future on a U.S.-centric innovation pipeline and blockbuster pet health drugs.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

Beyond the press release: How two strategic hires signal Plus Therapeutics' aggressive push to commercialize its CNSide platform and capture a $6B market.

A new lab system combines speed, multiplexing, and regulatory trust, promising to accelerate drug development and deepen our biological understanding.

A $900k stock grant to a new exec reveals more than a salary. It's a look into biotech's talent war and the financial tools used to secure human assets.